MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Soleno Therapeutics Market Cap 2011-2025 | SLNO
As of December 15, 2025 Soleno Therapeutics has a market cap of $ 2.08 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Soleno Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.96 B | 803 M | 17.4 M | 1.89 M | 156 M | 110 M | 36.1 M | 15.6 M | 13.1 M | 12.6 M | 1.69 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.96 B | 1.69 M | 284 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M |  USA |
|
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
709 M | $ 38.85 | 2.32 % | $ 1.08 B | USA |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 16.36 | -4.05 % | $ 176 M |  China |
 |
Brainsway Ltd.
BWAY
|
240 M | $ 17.05 | -2.15 % | $ 99.4 M |  Israel |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Danaher Corporation
DHR
|
152 B | $ 227.08 | -2.28 % | $ 166 B | USA |
 |
Exact Sciences Corporation
EXAS
|
9.32 B | $ 101.58 | 0.21 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 27.13 | 0.26 % | $ 820 M | USA |
 |
BioNano Genomics
BNGO
|
3.55 M | $ 1.63 | -2.11 % | $ 2.07 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
48.8 B | $ 66.91 | -2.94 % | $ 25.8 B | USA |
 |
DarioHealth Corp.
DRIO
|
43.4 M | $ 11.92 | -6.58 % | $ 338 M | Israel |
 |
Illumina
ILMN
|
16.4 B | $ 134.29 | -1.58 % | $ 21.4 B | USA |
 |
IQVIA Holdings
IQV
|
35.7 B | $ 221.54 | -1.96 % | $ 40.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Lantheus Holdings
LNTH
|
6.47 B | $ 66.11 | 4.76 % | $ 4.57 B | USA |
 |
Guardant Health
GH
|
5.84 B | $ 102.09 | 0.7 % | $ 12.5 B | USA |
 |
CareDx, Inc
CDNA
|
521 M | $ 20.44 | 3.23 % | $ 1.1 B | USA |
 |
Celcuity
CELC
|
399 M | $ 105.26 | 4.46 % | $ 4.15 B | USA |
 |
Anixa Biosciences
ANIX
|
70.8 K | $ 3.59 | -25.21 % | $ 115 K | USA |
 |
Co-Diagnostics
CODX
|
34.9 M | $ 0.34 | -2.96 % | $ 9.98 M | USA |
 |
Myriad Genetics
MYGN
|
973 M | $ 7.26 | -0.62 % | $ 658 M | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 6.86 | -2.63 % | $ 1.49 B | USA |
 |
National Research Corporation
NRC
|
1.01 B | $ 17.81 | 2.24 % | $ 437 M | USA |
 |
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
21.1 B | $ 263.51 | -0.46 % | $ 22.1 B | USA |
 |
Organovo Holdings
ONVO
|
3.1 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
9.12 M | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
1.41 B | $ 2.13 | -1.61 % | $ 540 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
30.8 B | $ 26.6 | -1.52 % | $ 20 B |  Niderland |
 |
Psychemedics Corporation
PMD
|
16.8 M | - | -1.84 % | $ 15.3 M | USA |
 |
Charles River Laboratories International
CRL
|
8.54 B | $ 192.57 | -0.96 % | $ 9.89 B | USA |
 |
Quidel Corporation
QDEL
|
10.6 B | $ 28.79 | -2.93 % | $ 1.21 B | USA |
 |
Quotient Limited
QTNT
|
183 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
RadNet
RDNT
|
3.68 B | $ 75.0 | -4.65 % | $ 5.48 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
19.1 B | $ 182.21 | 0.35 % | $ 20.2 B | USA |
|
Biodesix
BDSX
|
92.1 M | $ 7.94 | -1.0 % | $ 1.03 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 186.28 | -1.92 % | $ 15.4 B |  Irlanda |